Cited by 255Chromatin Remodeling and CancerCancer, Hypoxia, and MetabolismEpigenetics and DNA Methylation

The DOI matches its Crossref record; 100 of the 102 references it cites were found in a registry or an index.

KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer

Open access

Alam, Hunain, Tang, Ming, Maitituoheti, Mayinuer, Dhar, Shilpa S., Kumar, Manish, Han, Chae Young, Ambati, Chandrashekar R., Amin, Samir B., Gu, Bingnan, Chen, Tsai-Yu, Lin, Yu-Hsi, Chen, Jichao, Muller, Florian L., Putluri, Nagireddy, Flores, Elsa R., DeMayo, Francesco J., Baseler, Laura, Rai, Kunal, Lee, Min Gyu·2020·Cancer Cell

DOI 10.1016/j.ccell.2020.03.005PMC PMC7178078

Open this paper in CoChat — free account Open PDF

Abstract

Epigenetic modifiers frequently harbor loss-of-function mutations in lung cancer, but their tumor-suppressive roles are poorly characterized. Histone methyltransferase KMT2D (a COMPASS-like enzyme, also called MLL4) is among the most highly inactivated epigenetic modifiers in lung cancer. Here, we show that lung-specific loss of Kmt2d promotes lung tumorigenesis in mice and upregulates pro-tumorigenic programs, including glycolysis. Pharmacological inhibition of glycolysis preferentially impedes tumorigenicity of human lung cancer cells bearing KMT2D-inactivating mutations. Mechanistically, Kmt2d loss widely impairs epigenomic signals for super-enhancers/enhancers, including the super-enhancer for the circadian rhythm repressor Per2. Loss of Kmt2d decreases expression of PER2, which regulates multiple glycolytic genes. These findings indicate that KMT2D is a lung tumor suppressor and that KMT2D deficiency confers a therapeutic vulnerability to glycolytic inhibitors.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.ccell.2020.03.005

Cites

100 of 100 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
NIH Image to ImageJ: 25 years of image analysis
Schneider, C. A., Rasband, W. S., & Eliceiri, K. W. (2012) · Nature Methods · doi:10.1038/nmeth.2089 · Cited by 64,638
The Sequence Alignment/Map format and SAMtools
Li, H., Handsaker, B., Wysoker, A., Fennell, T., Ruan, J., Homer, N., Marth, G., Abecasis, G., Durbin, R., & 1000 Genome Project Data Processing Subgroup (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp352 · Cited by 62,041
Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
STAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
featureCounts: an efficient general purpose program for assigning sequence reads to genomic features
Liao, Y., Smyth, G. K., & Shi, W. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btt656 · Cited by 27,219
Ultrafast and memory-efficient alignment of short DNA sequences to the human genome.
Langmead, B., Trapnell, C., Pop, M., & Salzberg, S. L. (2009) · Genome Biology · doi:10.1186/gb-2009-10-3-r25 · Cited by 21,849
Model-based Analysis of ChIP-Seq (MACS)
Zhang, Y., Liu, T., Meyer, C. A., Eeckhoute, J., Johnson, D. S., Bernstein, B. E., Nusbaum, C., Myers, R. M., Brown, M., Li, W., et al. (2008) · Genome Biology · doi:10.1186/gb-2008-9-9-r137 · Cited by 18,386
The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data
Cerami, E., Gao, J., Dogrusoz, U., Gross, B. E., Sumer, S. O., Aksoy, B. A., Jacobsen, A., Byrne, C. J., Heuer, M. L., Larsson, E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0095 · Cited by 17,455
Integrative genomics viewer
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390

Show all 102 references

Sorted by citations

Items 101–200 of 255

Super-enhancers in tumors: unraveling recent advances in their role in Oncogenesis and the emergence of targeted therapies
Ji, Y., Li, B., Lin, R., Yuan, J. T., Han, Y., Du, Y., & Zhao, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06098-x · Cited by 14
Period circadian regulator 2 suppresses drug resistance to cisplatin by PI3K/AKT pathway and improves chronochemotherapeutic efficacy in cervical cancer
Wang, Z., Li, F.-Y., He, S., Zhao, L., & Wang, F. (2021) · Gene · doi:10.1016/j.gene.2021.146003 · Cited by 13
Downregulation of Ambra1 by altered DNA methylation exacerbates dopaminergic neuron damage in a fenpropathrin-induced Parkinson-like mouse model.
He, S., Qu, Q., Chen, X., Zhao, L., Jiao, Z.-G., Wan, Z.-T., Kwok, H.-F., & Qu, S.-G. (2024) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2024.115995 · Cited by 11
An IFN-γ-related signature predicts prognosis and immunotherapy response in bladder cancer: Results from real-world cohorts
Deng, H., Deng, D., Qi, T., Liu, Z., Wu, L., & Yuan, J. (2023) · Frontiers in Genetics · doi:10.3389/fgene.2022.1100317 · Cited by 13
Landscape of targeted therapies for lung squamous cell carcinoma
Chen, Q., Zheng, X.-S., Cheng, W., & Li, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1467898 · Cited by 15
Epigenetic Control of Redox Pathways in Cancer Progression
Shah, V., Lam, H. Y., Leong, C. H.-M., Sakaizawa, R., Shah, J., & Kumar, A. P. (2025) · Antioxidants and Redox Signaling · doi:10.1089/ars.2023.0465 · Cited by 12
A role for pH dynamics regulating transcription factor DNA-binding selectivity
Kisor, K. P., Ruiz, D. G., Jacobson, M. P., & Barber, D. L. (2025) · Nucleic Acids Research · doi:10.1093/nar/gkaf474 · Cited by 13
PFKP phenotype in lung cancer: prognostic potential and beyond
Ganapathy‐Kanniappan, S. (2020) · Molecular Biology Reports · doi:10.1007/s11033-020-05805-9 · Cited by 12
3D genomics and its applications in precision medicine
Chen, M.-J., Liu, X., Liu, Q.-Y., Shi, D., & Li, H. (2023) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-023-00428-x · Cited by 12
Targeting DNA Damage Response and Immune Crosstalk in Cancer: Mechanistic Insights and Therapeutic Opportunities
Mărcuț, L. F., Brata, R. D., Barb, A. C., Manole, A., Stef, D. G., Dumitru, C. Ș., Zara, F., & Pătrașcu, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262311271 · Cited by 11
Linc00996 is a favorable prognostic factor in LUAD: Results from bioinformatics analysis and experimental validation
Shen, Z., Li, X., Hu, Z., Yang, Y., Yang, Z., Li, S., Zhou, Y., Ma, J., Li, H., Liu, X., et al. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.932973 · Cited by 11
Histone lysine methyltransferase-related neurodevelopmental disorders: current knowledge and saRNA future therapies
Roth, C., Kilpinen, H., Kurian, M. A., & Barral, S. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1090046 · Cited by 11
Distinct mutational pattern of T-cell large granular lymphocyte leukemia combined with pure red cell aplasia: low mutational burden of STAT3
Park, S., Yun, J., Choi, S. Y., Jeong, D., Gu, J. Y., Lee, J., Seong, M., Chang, Y. H., Yun, H., & Kim, H. K. (2023) · Scientific Reports · doi:10.1038/s41598-023-33928-z · Cited by 12
The KDM6A-KMT2D-p300 axis regulates susceptibility to diverse coronaviruses by mediating viral receptor expression
Wei, J., Alfajaro, M. M., Cai, W. L., Graziano, V. R., Strine, M. S., Filler, R. B., Biering, S. B., Sarnik, S. A., Patel, S., Menasché, B. L., et al. (2023) · PLoS Pathogens · doi:10.1371/journal.ppat.1011351 · Cited by 10
Epigenetic and metabolic interplay in cutaneous squamous cell carcinoma
Pacella, G., & Capell, B. C. (2021) · Experimental Dermatology · doi:10.1111/exd.14354 · Cited by 11
High-Throughput Identification, Modeling, and Analysis of Cancer Driver Genes In VivoPreprint
Tang, Y. J., Shuldiner, E. G., Karmakar, S., & Winslow, M. M. (2023) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a041382 · Cited by 11
Effects of KMT2D mutation and its exon 39 mutation on the immune microenvironment and drug sensitivity in colorectal adenocarcinoma
Liu, C., Jin, Y., Zhang, H., Yan, J., Guo, Y., Bao, X., & Zhao, P. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e13629 · Cited by 11
The FBXW7–KMT2 axis in cancer-associated fibroblasts controls tumor growth via an epigenetic-paracrine mechanism
Yin, L., Zhang, J., Zhu, Z., Peng, X., Lan, H., Ayoub, A. M., Tan, M., Zhou, B. O., He, Y., Wang, S., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2423130122 · Cited by 10
RETRACTED ARTICLE: Circadian Period 2 (Per2) downregulate inhibitor of differentiation 3 (Id3) expression via PTEN/AKT/Smad5 axis to inhibits glioma cell proliferation
Zhang, Y., Hu, X., Li, H., Yao, J., Yang, P., Lan, Y., & Xia, H. (2022) · Bioengineered · doi:10.1080/21655979.2022.2074107 · Cited by 10
Retracted
Synthesis, crystal structure, computational investigation, molecular docking analysis and anti-lung cancer activity of novel (Z)-3-amino-2-(cyclohexylidenehydrazono)thiazolidin-4-one
Ghous, F., Shukla, S., Singh, R., Parveen, S., Banerjee, M., & Bishnoi, A. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.135462 · Cited by 10
Genomic Analyses of Metaplastic or Sarcomatoid Carcinomas From Different Organs Revealed Frequent Mutations in KMT2D
Zheng, B., Song, Z., Chen, Y., & Yan, W. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.688692 · Cited by 9
Genomic profiling of idiopathic peri-hilar cholangiocarcinoma reveals new targets and mutational pathways
Quinn, L. M., Haldenby, S. T., Antzcak, P., Fowler, A., Bullock, K., Kenny, J. G., Gilbert, T. M., Andrews, T., Díaz-Nieto, R., Fenwick, S. W., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-33096-0 · Cited by 9
KMT2D Loss Promotes Head and Neck Squamous Carcinoma Through Enhancer Reprogramming and Modulation of Immune MicroenvironmentPreprint
Callahan, S. C., Divenko, M., Barrodia, P., Singh, A. K., Arslan, E., Liu, Z., Yang, J., Anvar, N. E., Amit, M., Xie, T., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.09.21.461314 · Cited by 9
Self-citation
Kawain Inhibits Urinary Bladder Carcinogenesis through Epigenetic Inhibition of LSD1 and Upregulation of H3K4 Methylation
Xu, X., Tian, X., Song, L., Xie, J., Liao, J. C., Meeks, J. J., Wu, X., Gin, G. E., Wang, B., Uchio, E., et al. (2023) · Biomolecules · doi:10.3390/biom13030521 · Cited by 8
Targeting Epigenetic Dysregulations in Head and Neck Squamous Cell Carcinoma
Li, Y., & Lü, C. (2024) · Journal of Dental Research · doi:10.1177/00220345241297122 · Cited by 8
Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS
Dhar, S. S., Brown, C. J., Rizvi, A., Reed, L., Kotla, S., Zod, C., Abraham, J., Abe, J., Rajaram, V., Chen, K., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.115619 · Cited by 8
Self-citation
The role of KMT2 gene in human tumors.
Zhang, Z., Yu, P.-F., & Ling, Z. (2022) · PubMed · doi:10.14670/hh-18-447 · Cited by 7
Histone lysine methyltransferase SETDB2 suppresses NRF2 to restrict tumor progression and modulates chemotherapy sensitivity in lung adenocarcinoma
Yuan, G., Hu, B., Ma, J., Zhang, C., Xie, H., Wei, T., Yang, Y., & Ni, B. (2022) · Cancer Medicine · doi:10.1002/cam4.5451 · Cited by 8
HDAC4 super-enhancer drives CEBPB-mediated TWIST2 transcription to promote chemoresistance in LUAD
Jiang, M., Zhang, K., Wei, G., Qi, F., Yu, D., Jingjing, M., Zhang, X., 陈龙邦, Xie, Y., Yu, Z., et al. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217716 · Cited by 7
Self-citation
Mutational Landscape of Bladder Cancer in Mexican Patients: KMT2D Mutations and chr11q15.5 Amplifications Are Associated with Muscle Invasion
Pérez‐Montiel, D., Cerrato-Izaguirre, D., Sánchez-Pérez, Y., Díaz‐Chávez, J., Cortés-González, C. C., Rubio, J. A., Jiménez-Ríos, M. Á., Herrera, L. A., Scavuzzo, A., Meneses-García, A. A., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021092 · Cited by 7
Identification of novel miRNAs potentially involved in the pathogenesis of adult T-cell leukemia/lymphoma using WGCNA followed by RT-qPCR test of hub genes
Shayeghpour, A., Forghani-Ramandi, M.-M., Solouki, S., Hosseini, A., Hosseini, P., Khodayar, S., Hasani, M., Aghajanian, S., Siami, Z., Ghobadi, M. Z., et al. (2023) · Infectious Agents and Cancer · doi:10.1186/s13027-023-00492-0 · Cited by 6
ACAT2 may be a novel predictive biomarker and therapeutic target in lung adenocarcinoma
Wang, Z., Cao, Z., & Dai, Z. (2024) · Cancer Reports · doi:10.1002/cnr2.1956 · Cited by 7
KMT2D deficiency confers a therapeutic vulnerability to glycolytic and IGFR inhibitors in melanoma
Murugesan, N., & Maitituoheti, M. (2021) · Molecular & Cellular Oncology · doi:10.1080/23723556.2021.1984827 · Cited by 7
Self-citation
RNA-SSNV: A Reliable Somatic Single Nucleotide Variant Identification Framework for Bulk RNA-Seq Data
Long, Q., Yuan, Y., & Li, M. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.865313 · Cited by 6
Unveiling the Molecular Landscape of Pancreatic Ductal Adenocarcinoma: Insights into the Role of the COMPASS-like Complex
Jamali, M., Barar, E., & Shi, J. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25105069 · Cited by 6
Deficiency of TET2-mediated KMT2D self-transcription confers a targetable vulnerability in hepatocellular carcinoma
Jin, Y., Rao, K., Zheng, J., Zhang, X., Luo, Y., & He, J. (2024) · PNAS Nexus · doi:10.1093/pnasnexus/pgae504 · Cited by 6
Developmental Insights into Lung Cancer
Desai, T. (2021) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-070820-032858 · Cited by 6
Non-genetic stratification reveals epigenetic heterogeneity and identifies vulnerabilities of glycolysis addiction in lung adenocarcinoma subtype
Song, X., Zhang, T., Ding, H., Feng, Y., Yang, W., Yin, X., Chen, B., Liang, Y., Mao, Q., Xia, W., et al. (2022) · Oncogenesis · doi:10.1038/s41389-022-00436-0 · Cited by 6
Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer
Zheng, J., Zhang, Y., Han, G., Fan, M., Du, M.-H., Zhang, G., Zhang, B., Qiao, J., Zhang, S., & Cao, J. (2022) · Advances in Therapy · doi:10.1007/s12325-022-02330-y · Cited by 6
Synthesis, in-Silico investigations, molecular docking, ADMET, and anti-lung cancer activity studies of 1,2,4,5-tetraazaspiro[5.5]undecane-3-thione
Ghous, F., Rai, S., Kumar, S., Banerjee, M., & Bishnoi, A. (2023) · Chemical Physics · doi:10.1016/j.chemphys.2023.112053 · Cited by 6
KB-68A7.1 Inhibits Hepatocellular Carcinoma Development Through Binding to NSD1 and Suppressing Wnt/β-Catenin Signalling
Zhang, S., Xu, J., Cao, H., Jiang, M., & Xiong, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.808291 · Cited by 6
Multifaceted regulation of enhancers in cancer
Xiao, Q., Xiao, Y., Li, L., Chen, M., & Wu, M. (2022) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2022.194839 · Cited by 6
The landscape of enhancer RNA identify prognosis‐related molecular subtypes in gastric cancer
Yan, A., Chen, Y., Bian, R., Wang, C., Que, H., Shen, Y., & Lu, X. (2022) · Cancer Medicine · doi:10.1002/cam4.4959 · Cited by 5
Molecular characterization of an embryonal rhabdomyosarcoma occurring in a patient with Kabuki syndrome: report and literature review in the light of tumor predisposition syndromes
Aukema, S., Glaser, S., van den Hout, M. F. C. M., Dahlum, S., Blok, M. J., Hillmer, M., Kolarova, J., Sciot, R., Schott, D. A., Siebert, R., et al. (2022) · Familial Cancer · doi:10.1007/s10689-022-00306-z · Cited by 6
The histone-modified landscape: Core mechanisms of osimertinib resistance in EGFR-mutant lung cancer
Yang, J., Zhang, M., Gao, C., Yao, X., Sun, C., & Zhuang, J. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218321 · Cited by 7
Pathogenic role of super-enhancers as potential therapeutic targets in lung cancer
Yao, Z., Song, P., & Jiao, W. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1383580 · Cited by 6
Mapping in silico genetic networks of the KMT2D tumour suppressor gene to uncover novel functional associations and cancer cell vulnerabilities
Takemon, Y., Pleasance, E., Gagliardi, A., Hughes, C. S., Csizmók, V., Wee, K., Trinh, D. L. N., Huff, R. D., Mungall, A. J. J., Moore, R. A., et al. (2024) · Genome Medicine · doi:10.1186/s13073-024-01401-9 · Cited by 7
Somatic KMT2D loss-of-function mutations in lung squamous cell carcinoma: a single-center cohort study
Fang, Z., Wu, X., Li, X., Wang, C., Zhao, Y., Zhang, Q., Jablonska, P. A., Rosa, A. L., Dempke, W. C. M., Furqan, M., et al. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-134 · Cited by 5
The roles of enhancer, especially super-enhancer-driven genes in tumor metabolism and immunity
Guo, S., Zhang, L., Ren, J., Lü, Z., Ma, X., Liu, X., Jin, H., & Li, J. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.142414 · Cited by 6
Pathological and genomic phenotype of second neuroendocrine carcinoma during long-term follow-up after radical radiotherapy for nasopharyngeal carcinoma
Peng, Y., Liu, Q., Lin, Y.-J., Peng, S., Wang, R., Xu, X., Wei, W., Zhong, G., Zhou, Y., Zhang, Y., et al. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01898-z · Cited by 5
Self-citation
Super-enhancer DNA methylation in cancer: the mechanism of action and therapeutic directions
Bi, Y., Zou, K., & Wang, K. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1610579 · Cited by 4
Identification of Candidate mRNA Genes and Their Potential MicroRNA Targets in Lung Cancer Induced by Smoking Tobacco
Mishra, A. K., Mumtaz, N., & Misra, M. K. (2023) · Frontiers in Bioscience-Scholar · doi:10.31083/j.fbs1504013 · Cited by 4
KMT2D: A key emerging epigenetic regulator in head and neck diseases and tumors
Wang, K., Zhan, F., Yang, X., Jiao, M., Wang, P., Zhang, H., Shang, W., Deng, J., & Wang, L. (2025) · Life Sciences · doi:10.1016/j.lfs.2025.123523 · Cited by 4
Advances in Computational Drug Repurposing, Driver Genes, and Therapeutics in Lung Adenocarcinoma
Nematzadeh, S., & Karaul, A. (2025) · Biomolecules · doi:10.3390/biom15101373 · Cited by 4
Chrono-immunotherapy’s current and future optimization strategies: immunotherapy timing in line with the circadian rhythm brings longer survival benefits
Liu, D., Li, Z., Cui, H., Zhang, H., Li, H., & Wu, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1777437 · Cited by 4
Genomic and Gene Expression Studies Helped to Define the Heterogeneity of Small-Cell Lung Cancer and Other Lung Neuroendocrine Tumors and to Identify New Therapeutic Targets
Testa, U., Pelosi, E., & Castelli, G. (2022) · Onco · doi:10.3390/onco2030013 · Cited by 4
Bioinformatics Pipelines for Identification of Super-Enhancers and 3D Chromatin Contacts
Sakashita, A., Takeuchi, C., Maezawa, S., & Namekawa, S. H. (2022) · Methods in molecular biology · doi:10.1007/978-1-0716-2724-2_9 · Cited by 3
Alterations of histone modifications in cancer
Saber-Ayad, M. M., Ramadan, W. S. H., & El‐Awady, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-18661-5.00018-x · Cited by 5
KMT2D preferentially binds mRNAs of the genes it regulates, suggesting a role in RNA processing
Amin, H. M., Abukhairan, R., Szabó, B., Jacksi, M., Várady, G., Lózsa, R., Schád, É., & Tantos, Á. (2023) · Protein Science · doi:10.1002/pro.4847 · Cited by 4
HACE1 as a bridge between oxidative stress and autophagy
Xia, J., Jiang, Y., Xin, X., Li, T., Liao, W., & Xin, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1595601 · Cited by 3
Cancer Genomic Alterations and Microenvironmental Features Encode Synergistic Interactions with Disease Outcomes
Bayati, M., Klein, Z. P., Bahcheli, A. T., Slobodyanyuk, M., To, J. C., Cheng, K. C. L., Mishra, J., Pellegrina, D. V. D. S., Guevara‐Hoyer, K., McIntosh, C., et al. (2025) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-25-0475 · Cited by 3
Circadian regulation of vascular function: Metabolism as a link from molecular mechanisms to clinical implications
Wang, F., Peng, Y., Yu, H., Gan, L., & Cao, Y. (2025) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2025.168048 · Cited by 3
KMT2D loss drives adeno-to-squamous transition and sensitizes TKI-resistant lung cancer to AURKA inhibition
Chen, N., Fang, M., Zhong, L., Li, X., Zhou, Y., Zhan, J., Wang, M., Fang, Z., Wang, H., Tang, S., et al. (2026) · Cell Death and Differentiation · doi:10.1038/s41418-025-01657-7 · Cited by 4
Enhancer and metabolic rewiring by KMT2C–COMPASS or KMT2D–COMPASS family loss in cancer creates druggable vulnerabilities
Zhao, Z., & Shilatifard, A. (2026) · Nature reviews. Cancer · doi:10.1038/s41568-026-00919-x · Cited by 4
Application of biomechanics in tumor epigenetic research
Wang, Q., Yin, X., Ding, Y., Zhao, H., & Luo, Y. (2024) · Mechanobiology in Medicine · doi:10.1016/j.mbm.2024.100093 · Cited by 4
Superenhancer–transcription factor regulatory network in malignant tumors
Liang, Y., Li, L., Tian, X., Li, B., & Zhang, D. (2021) · Open Medicine · doi:10.1515/med-2021-0326 · Cited by 3
PSC subtyping based on TTF ‐1 and p40 expression reveals distinct molecular characteristics and therapeutic strategies
Yang, Z., Tian, H., Li, L., Li, C., Xu, J., Bie, F., Chen, Y., Tian, Y., Bai, G., Peng, Y., et al. (2022) · International Journal of Cancer · doi:10.1002/ijc.34137 · Cited by 3
Histone methyltransferase KMT2D inhibits ENKTL carcinogenesis by epigenetically activating SGK1 and SOCS1
Zhang, Y.-H., Tao, Q., Zhang, W., Zhao, S., Liu, W.-P., & Gao, L. (2023) · Genes & Genomics · doi:10.1007/s13258-023-01434-1 · Cited by 3
Genetic Variants in Double-Strand Break Repair Pathway Genes to Predict Platinum-Based Chemotherapy Prognosis in Patients With Lung Cancer
Liu, J., Zou, T., Yin, J., Wang, Z., Liu, C., Huang, H., Ding, F.-X., Lei, M., Wang, Y., Liu, M., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.915822 · Cited by 3
Self-citation
Novel Driver Strength Index highlights important cancer genes in TCGA PanCanAtlas patients
Belikov, A. V., Otnyukov, D. V., Vyatkin, A. D., & Leonov, S. V. (2022) · PeerJ · doi:10.7717/peerj.13860 · Cited by 3
Loss of epigenetic regulation disrupts lineage integrity, reactivates multipotency and promotes breast cancerPreprint
Langille, E. R., Al‐Zahrani, K. N., Ma, Z., Malik, A., Loganathan, S. K., Trcka, D., Liu, J., Kozma, K. J., Tsai, R., Teng, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.22.465428 · Cited by 3
Whole genome sequencing and single-cell transcriptomics identify KMT2D inactivation as a potential new driver for pituitary tumors: a case report
Brunner, M., Meylan-Merlini, J., Muriset, M., Oreshkov, S., Messina, A., Messerer, M., Daniel, R. T., Hewer, E., Brouland, J., & Santoni, F. A. (2025) · BJC Reports · doi:10.1038/s44276-025-00155-0 · Cited by 2
Validation of a Proteomic Signature of Lung Cancer Risk from Bronchial Specimens of Risk-Stratified Individuals
Rahman, S. M. J., Chen, S., Wang, Y.-T., Gao, Y., Schepmoes, A., Fillmore, T., Shi, T., Chen, H., Rodland, K., Massion, P. P., et al. (2023) · Cancers · doi:10.3390/cancers15184504 · Cited by 2
Harnessing Machine Learning and Multiomics to Construct a Tumor-Specific T Cell Signature for Prognostic Assessment and Precision Medicine in Lung Adenocarcinoma
Shang, F., Huang, M., Ji, Y., Zhang, S., Fan, C., Zhang, K., Fang, Y., Li, X., Gu, L., Guan, Z., et al. (2025) · Annals of Surgical Oncology · doi:10.1245/s10434-025-18330-5 · Cited by 2
KMT2D temporally activates neuronal transcriptional factor genes to mediate cerebellar granule cell differentiation
Dhar, S. S., Ko, K.-P., Jang, J., Brown-Abel, C., Lin, T., Awasthi, S., Chen, K., Sillitoe, R. V., Park, J., & Lee, M. G. (2025) · Science Advances · doi:10.1126/sciadv.adu7174 · Cited by 2
Self-citation
Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer
Xue, C., Li, H., Yao, H., Lin, Y., An, X., Chen, M., Huang, R., Li, L., Hu, A., Ni, M., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00501-2 · Cited by 2
Self-citation
High expression of KMT2D is a promising biomarker for poor gastric cancer prognosis.
Yi, T., Peng, L., Li, P., He, Y., & Tian, J. (2023) · PubMed Central · Cited by 2
Activation of Wnt/β-catenin signalling by mutually exclusive FBXW11 and CTNNB1 hotspot mutations drives salivary gland basal cell adenomaPreprint
Wong, K., Bishop, J. A., Weinreb, I., Motta, M., Velasco‐Herrera, M. D. C., Bellacchio, E., Ferreira, I., van der Weyden, L., Boccacino, J. M., Rotundo, G., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.10.21.619442 · Cited by 2
Histone-Lysine N-Methyltransferase 2D (KMT2D) Impending Therapeutic Target for the Management of Cancer: The Giant Rats Tail
Jasmin, M. D. C., Narayanaswamy, R., Prabhu, V. V., Sakthivel, K. M., & Radha, R. R. (2024) · Journal of Environmental Pathology Toxicology and Oncology · doi:10.1615/jenvironpatholtoxicoloncol.2024053872 · Cited by 1
Histone-modifying enzymes and gastric cancer: Search for potential biomarkers and therapeutic targets based on Mendelian randomization
Liu, W., Wang, Z., Yang, Z., Huo, B., Song, Y., Li, Y., & Tan, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e38582 · Cited by 1
What Is On the Horizon for the Diagnosis and Treatment of SCLC and Large Cell Neuroendocrine Cancer?
Lim, S. M., Shim, J. S. G., Shim, H. S., Tanizaki, J., Nützinger, J., Cho, B. C., & Soo, R. A. (2025) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2025.100871 · Cited by 2
HSF1 promotes malignant phenotype in colorectal cancer via super-enhancer-driven lncRNA EXOSC10-AS1 and targeting HSF1 confers sensitivity to poly (ADP-ribose) polymerase inhibitor Niraparib
Song, P., Liu, X., Shen, Q., Yu, Y., Guo, S., Ren, J., Zhang, L., Zhu, L., Zhang, J., Sun, Y., et al. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148656 · Cited by 1
KDM6A phosphorylation suppresses PER2 to confer a glycolytic vulnerability in HNSCC
Chen, J., Ji, Y., Chen, X., Zhang, M., Zhang, M., Hu, X. Y., Xu, X., Zhang, Y., Zhang, Z., Pan, X., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-08130-w · Cited by 1
Self-citation
A Super‐Enhancer‐Related Ferroptosis Signature Predicts Survival and Immune Microenvironment in Colon Cancer Based on Bioinformatics Analyses and Experimental Validation
Wan, L., Li, J. J., & Xie, X. (2025) · IET Systems Biology · doi:10.1049/syb2.70043 · Cited by 1
Histone methyltransferase KMT2D promotes castration-resistant prostate cancer progression by reactivating AR through FOXA1
Luo, M., Wu, C., Zhou, M., Liu, R., Zhang, Y., Li, Y., Liao, Y., Huang, X. Y. S., Du, C., Lv, S., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03828-3 · Cited by 1
Temporal control of sgRNA library activation unlocks large-scale in vivo CRISPR screens
Fenoglio, S., Yu, Y., Tepper, J., Grove, L., Bejnood, A., Meier, S. R., Choi, A. H., Wu, H., Devault, A., Liu, S., et al. (2026) · Cell Reports Methods · doi:10.1016/j.crmeth.2026.101470 · Cited by 1
Mediator Subunit Med4 Enforces Metastatic Dormancy in Breast Cancer
Bae, S.-Y., Ling, H.-H., Zhang, J., Chen, Y., Chen, H., Kumar, D., Saw, A., Rai, K., Viny, A., DePinho, R., et al. (2023) · bioRxiv · doi:10.1038/s41556-026-01984-y · Cited by 1
Self-citation
Functional deficiency of circadian regulator PER2 enhances breast cancer susceptibility and progression with immunosuppression
Duan, Y., Alexandrou, A. T., Huang, J., Zhang, H. S., Zhang, H., Zhang, X., Hao, D., Berg, J. I., Fan, M., Wang, Y., et al. (2026) · Oncogene · doi:10.1038/s41388-026-03941-3 · Cited by 1
Integrated Analysis of Multi-Omics Data to Establish a Hypoxia-Related Prognostic Model in Osteosarcoma
Ye, T., Zhang, X., & Zhou, Y. (2022) · Evolutionary Bioinformatics · doi:10.1177/11769343221128537 · Cited by 1
Genomic evolutional analysis of surgical resected specimen to assess osimertinib as a first‐line therapy in two patients with lung cancer harboring EGFR mutation: Case series
Koba, H., Yoneda, T., Morita, H., Kimura, H., Murase, Y., Terada, N., Tambo, Y., Horie, M., Kasahara, K., Matsumoto, I., et al. (2024) · Thoracic Cancer · doi:10.1111/1759-7714.15241 · Cited by 1
DYNLL1 ubiquitinated and degraded by E3 ligase PRKN regulates cell cycle arrest and apoptosis in lung adenocarcinoma cells
Tang, H., & Wei, C. (2024) · Discover Oncology · doi:10.1007/s12672-024-01686-7 · Cited by 1
Identifying KDM5B as the synthetic lethal target of KMT2D-mutated osteosarcoma
Yang, L., Zhang, J., Jiang, Y., Zhang, J., Wang, Z., Wang, L., Fan, X., & Ba, G. (2025) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2025.111451 · Cited by 1
RBAP48 facilitates the oral squamous cell carcinoma process in an androgen receptor-dependent and independent manners
Wang, X., Yan, G., Li, H., Wang, C., Kang, Y., Wang, S., Liu, W., Lin, L., Zou, R., Zeng, K., et al. (2025) · Communications Biology · doi:10.1038/s42003-025-08215-4 · Cited by 1
KMT2D upregulates SMG1 via histone methylation to antagonize mTOR and reinforce DLBCL ferroptosis
Sun, Y., Xu, Z., Wang, Z., Zhang, Y., Zhang, P., Sheng, L., Yang, S., & Ouyang, G. (2025) · Journal of Leukocyte Biology · doi:10.1093/jleuko/qiaf092 · Cited by 1
Metabolic Reprogramming by Histone Deacetylase Inhibition Selectively Targets NRF2-activated tumorsPreprint
Karagiannis, D., Wu, W., Li, A. M., Hayashi, M., Chen, X., Yip, M., Mangipudy, V. S., Xu, X., Rivera, F. J. S., Soto‐Feliciano, Y. M., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.24.538118 · Cited by 1
A Lung Cancer Mouse Model DatabasePreprint
Cai, L., Gao, Y., DeBerardinis, R. J., Acquaah-Mensah, G. K., Aidinis, V., Beane, J., Biswal, S. S., Chen, T., Concepcion, C. P., Grüner, B. M., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.02.28.582577 · Cited by 1
Self-citation
Loss of Kmt2c / d promotes gastric cancer initiation and confers vulnerability to mTORC1 inhibition and anti-PD1 immunotherapyPreprint
Wang, N., Li, D., Zhang, T., Pachai, M. R., Cho, W. H., Khudoynazarova, M. N., Schoeps, D. M., Bao, Y., Liu, M., Tang, L. H., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.27.645747 · Cited by 1
Deciphering Cellular Ecosystems Driving Tumor Progression and Immune Escape from Spatial Transcriptomics and Single-Cell with COMPOTESPreprint
Herpin, L., Chossegros, A., Codato, R., Sanchez, J. M., Khoury, J. E., Grouard, S., Ducret, V., Cornish, A. J., Gross, B., Pronier, E., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.10.27.684744 · Cited by 1
Tumor’s loss is clinician’s gain
Ferrarelli, L. K. (2020) · Science Signaling · doi:10.1126/scisignal.abc5604
Grainyhead-like 2 Sensitizes Cells to Natural Killer Cell Cytotoxicity and Promotes the Interferon Response
MacFawn, I. (2020) · doi:10.33915/etd.7778

Authors: Alam, H., Tang, M., Maitituoheti, M., Dhar, S. S., Kumar, M., Han, C. Y., Ambati, C. R., Amin, S. B., Gu, B., Chen, T.-Y., Lin, Y.-H., Chen, J., Muller, F. L., Putluri, N., Flores, E. R., DeMayo, F. J., Baseler, L., Rai, K., & Lee, M. G.
Affiliations: The University of Texas MD Anderson Cancer Center (US)
Baylor College of Medicine (US)
Moffitt Cancer Center (US)
National Institute of Environmental Health Sciences (US)
Corresponding author: Rai, Kunal
Lee, Min Gyu
ORCID: Alam, Hunain
Tang, Ming
Maitituoheti, Mayinuer
Dhar, Shilpa S.
Kumar, Manish
Han, Chae Young
Ambati, Chandrashekar R.
Chen, Tsai-Yu
Lin, Yu-Hsi
Chen, Jichao
Putluri, Nagireddy
Flores, Elsa R.
DeMayo, Francesco J.
Rai, Kunal
Lee, Min Gyu
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2020-04
Volume: 37
Issue: 4
Pages: 599-617.e7
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccell.2020.03.005
PMC: PMC7178078
OpenAlex: W3014830213
Cited by: 243
References: 102
Citations by year: 2026: 28 · 2025: 39 · 2024: 38 · 2023: 53 · 2022: 42 · 2021: 35 · 2020: 8
FWCI: 11.99
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 377 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: University of Texas MD Anderson Cancer Center (R00CA160578)
National Cancer Institute (P30CA016672)
American Cancer Society (RSG-15-145-01-CDD)
National Institutes of Health (R01CA207109, R01CA157919, R01CA207098)
National Institute of Environmental Health Sciences (Z1AES103311-10, R35CA197452)
Cancer Prevention and Research Institute of Texas (RP170005, 127430-RSG-15-105-01-CNE)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
Keywords: KMT2D, histone methyltransferase, lung cancer, super-enhancers, enhancers, glycolysis, glycolysis inhibitors, Per2, circadian rhythm, tumor suppressor, epigenetic regulators, loss-of-function mutations, lung carcinogenesis
MeSH terms: Adenocarcinoma of Lung, Animals, Antimetabolites, Deoxyglucose, DNA-Binding Proteins, Enhancer Elements, Genetic, Glycolysis, Histones, Humans, Lung Neoplasms, Mice, Nude, Mutation, Neoplasm Proteins, Prognosis, Histone-Lysine N-Methyltransferase, Tumor Cells, Cultured, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Apoptosis, Mice, Knockout, Xenograft Model Antitumor Assays, Cell Proliferation, Mice, Myeloid-Lymphoid Leukemia Protein, Period Circadian Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

KMT2D Deficiency Impairs Super-Enhancers to Confer a Glycolytic Vulnerability in Lung Cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks